ArticlePLoS neglected tropical diseases2025
Validation of the Brugia Test Plus to detect IgG4 antibodies in individuals from Belitung Timur, a Brugia malayi endemic area in Indonesia.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Can mass drug administration alone eliminate lymphatic filariasis in areas of Indonesia with zoophilic Brugia malayi?PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The Brugia Test Plus (BT+) is a new rapid diagnostic test for Brugia species which detects human IgG4 antibodies specific for the immunogenic Brugia protein BmR1. The aim of this study was to evaluate the BT+ assay with several types of sample-matrices: whole blood, plasma, and dried blood spots (DBS) from individuals living in Belitung Timur, a Brugia malayi endemic area in Indonesia. Night blood was collected from residents living in four presumed endemic villages, while DBS were collected from schoolchildren living in those four villages. The sensitivity of BT+ was measured by comparing the BT+ results to microscopic examination for microfilaria (Mf). The sensitivity of BT+ with whole blood under field conditions was 84.9% (95% CI 68.1-94.9, n = 33), and with EDTA plasma under laboratory conditions was 95.9% (95% CI 88.5-99.1, n = 73). Specificity was not assessed as it is impossible do so for an antibody test in endemic areas. In Mf-negative individuals, BT+ detected IgG4 antibodies in 204 out of 1,547 adult plasma samples (13.2%) and 7 out of 146 plasma samples collected from children aged 10-16 (4.8%). Detection of IgG4 antibodies in DBS collected from first and second grade schoolchildren (age 6-8) showed that only 1 out of 244 schoolchildren was positive (0.1%). Three individual readers were responsible for reading the BT+ . Statistical analysis showed high agreement among those readers (Kappa agreement value above 0.9). Laboratory technicians found the BT+ is simple to perform, easy to interpret the results, and appreciated the small volume of blood required (5 µL). This study has demonstrated that the novel BT+ is feasible for teams to implement and achieves good sensitivity, making it well suited for monitoring and evaluating the progress of the brugian- filariasis elimination program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.